Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to ...
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
Source: eagletribune.com